
|Articles|April 1, 2003
Combination Therapy Safe
Maui, Hawaii - Preliminary results from an open-label study suggest PUVA-bexarotene is a safe and effective combination regimen for the treatment of early cutaneous T-cell lymphoma (CTCL), Joan Guitart, M.D., said at the annual Hawaii Dermatology Seminar, sponsored by the Skin Disease Education Foundation.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
2
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
3
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
4
Phase 2 Nemolizumab Trial Opens for CPUO
5


















